AVITA Medical Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

AVITA Medical hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	2.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$1.73
Erwartete Dividendenrendite in 3 Jahren	0%

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?

Jun 18

Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding

Apr 12

AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39%

Feb 02

The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32%

Oct 20

Avita Medical appoints James Corbett as CEO

Sep 29

AVITA Medical says trial evaluating its RECELL system to treat vitiligo met main goal

Sep 12

Avita's burn therapy Recell gets insurance coverage in Japan following approval

Sep 01

AVITA Medical GAAP EPS of -$0.25 beats by $0.15, revenue of $8.34M beats by $1.18M

Aug 11

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von RCEL in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von RCEL gestiegen sind.

Dividendenrendite im Vergleich zum Markt

AVITA Medical Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von RCEL im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (RCEL)	n/a
Untere 25 % des Marktes (US)	1.5%
Markt Top 25 % (US)	4.8%
Branchendurchschnitt (Biotechs)	2.8%
Analystenprognose in 3 Jahren (RCEL)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von RCEL im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von RCEL im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von RCEL, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da RCEL keine Ausschüttungen gemeldet hat.

AVITA Medical Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?

New minor risk - Shareholder dilution

AVITA Medical, Inc. Announces FDA Approval of RECELL GO

Consensus EPS estimates fall by 19%

No longer forecast to breakeven

AVITA Medical, Inc. Provides Earnings Guidance for the Second of 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

AVITA Medical, Inc., Annual General Meeting, Jun 05, 2024

Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding

New minor risk - Share price stability

AVITA Medical, Inc. Revises Revenue Guidance for the First Quarter Ended March 31, 2024 and Full Year Fiscal 2024

AVITA Medical, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39%

AVITA Medical, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Avita Medical, Inc. Provides Preliminary Revenue Guidance for Fourth Quarter and Full-Year 2023 and First Quarter and Year 2024

Forecast to breakeven in 2026

New minor risk - Insider selling

New minor risk - Profitability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

AVITA Medical, Inc. to Report Q3, 2023 Results on Nov 09, 2023

The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32%

AVITA Medical, Inc. announced that it expects to receive $90 million in funding from OrbiMed Advisors LLC

AVITA Medical, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023

AVITA Medical, Inc. to Report Q2, 2023 Results on Aug 10, 2023

AVITA Medical, Inc. Submits FDA PMA Supplement for Recell Go

AVITA Medical, Inc. Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients

AVITA Medical, Inc. Announces Appointment of David O’Toole as Chief Financial Officer

AVITA Medical Announces FDA Approval of RECELL for Treatment of Full-Thickness Skin Defects

AVITA Medical, Inc. Expects FDA Submission of Recell Go by June 30, 2023

AVITA Medical, Inc. Announces Executive Changes

AVITA Medical, Inc. to Report Q4, 2022 Results on Feb 23, 2023

AVITA Medical, Inc. Submits FDA PMA Application for Vitiligo

AVITA Medical, Inc. Submits PMA Supplement for Soft Tissue Repair

AVITA Medical, Inc. Revises Financial Guidance for the Year 2022

AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL System for Soft Tissue Repair

AVITA Medical, Inc. to Report Q3, 2022 Results on Nov 10, 2022

AVITA Medical, Inc., Annual General Meeting, Dec 12, 2022

AVITA Medical, Inc. Announces Executive Changes

AVITA Medical, Inc. Announces Chief Executive Officer Changes

Avita Medical appoints James Corbett as CEO

AVITA Medical, Inc. Announces Positive Topline Results from A Pivotal Randomized, Controlled Trial Evaluating the Safety and Effectiveness of the RECELL® System for Repigmentation of Stable Vitiligo Lesions

AVITA Medical says trial evaluating its RECELL system to treat vitiligo met main goal

RECELL Insurance Coverage Begins in Japan for Acute Burns

Avita's burn therapy Recell gets insurance coverage in Japan following approval

AVITA Medical, Inc. Announces Topline Results from Pivotal Trial in Patients with Soft-Tissue Injuries Using the Recell System

AVITA Medical GAAP EPS of -$0.25 beats by $0.15, revenue of $8.34M beats by $1.18M

AVITA Medical, Inc. to Report Q2, 2022 Results on Aug 11, 2022

AVITA Medical, Inc.(NasdaqCM:RCEL) dropped from Russell 2000 Growth Index

Avita Medical, Inc. Provides Guidance for Year 2022

Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors

AVITA Medical, Inc. Provides Revenue Guidance for the Calendar Year 2022

AVITA (AVH) Announces RECELL Receives Japan PMDA Approval

AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use

AVITA Medical, Inc. to Report First Half, 2022 Results on Feb 28, 2022

AVITA Medical, Inc. Establishes Proof of Concept for Gene Therapy

AVITA Medical Is Interesting, But Not Just Yet

AVITA Medical, Inc. Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Repigmentation of Stable Vitiligo

AVITA Medical, Inc. Provides Revenue Guidance for the First Quarter of Fiscal Year 2022

FDA Approves IDE Amendment to a Single-Arm Design for AVITA Medical, Inc.'s Pivotal Study of the RECELL® System for Vitiligo Treatment

AVITA Medical, Inc. Provides Revenue Guidance for the Fourth Quarter Ending June 30, 2021

Avita Medical, Inc. Announces Preliminary Unaudited Financial Results for the Fiscal Fourth Quarter Ending June 30, 2021

U.S. Food and Drug Administration Approves Expanded Use of the RECELL® System for the Treatment of Extensive Burns and Pediatric Patients

AVITA Medical, Inc. Provides Earnings Guidance for 2021

AVITA Medical, Inc. Will Not Provide Financial Guidance At This Time

AVITA Medical, Inc. to Report Q2, 2021 Results on Feb 11, 2021

AVITA Medical reports preliminary Q2 revenue in-line with consensus

AVITA Therapeutics, Inc. Appoints Kathy McGee as Chief Operating Officer, Effective December 1, 2020

AVITA: COVID-19's Impact

AVITA Therapeutics and the Houston Methodist Research Institute Enter into Collaboration to Explore Novel Approaches for Skin Rejuvenation

AVITA Therapeutics, Inc. Announces Executive Changes

AVITA Therapeutics, Inc. to Report Q1, 2021 Results on Nov 11, 2020

AVITA Therapeutics, Inc. to Report Q4, 2020 Results on Aug 27, 2020

AVITA Therapeutics Files Form 15

Stabilität und Wachstum des Zahlungsverkehrs